Infant Bacterial Therapeutics

Infant Bacterial Therapeutics AB, a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company focuses on late onset neonatal infection, a disease caused by an imbalance in the infant’s gut microbiota. Its lead drug candidate is IBP-9414 is being developed for the treatment of lactobacillus plantarum, enterococcus faecium and escherichia coli infections in preterm infants. The company was formerly known as Enterome AB and changed its name to Infant Bacterial Therapeutics AB in August 2012. Infant Bacterial Therapeutics AB is based in Stockholm, Sweden. As of March 4, 2015, Infant Bacterial Therapeutics AB operates as a subsidiary of Tim Medical Holdings Limited.

Latest events on Quartr

Previous Events for Infant Bacterial Therapeutics

Ticker

IBT

Country

Sweden

About the company

https://ibtherapeutics.com/

Investor Relations page

https://ibtherapeutics.com/sv/investerare/ir-contact/

Dig deeper into the fundamentals using Quartr - Investor relations

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
Android play link
App store link
Quartr app screenshot